<DOC>
	<DOC>NCT00085891</DOC>
	<brief_summary>The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.</brief_summary>
	<brief_title>Efficacy &amp; Safety of Quetiapine Fumarate (SEROQUEL) &amp; Placebo in the Treatment of Acutely Ill Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient is able to provide written informed consent before beginning any study related procedures Patient has a documented clinical diagnosis of schizophrenia Patient is able to understand and comply with the requirements of the study, as judged by a study investigator Patients with a history of noncompliance as judged by the study investigator Patients with a known lack of response to previous treatment with quetiapine Patients who have participated in another drug study within 4 weeks prior to enrollment into this study Patients who have previously participated in this study or study D1444C00132</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic disorder</keyword>
</DOC>